- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.08. | NeuroSense Issues CEO Letter to Shareholders | 266 | PR Newswire | CAMBRIDGE, Mass., Aug. 13, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused... ► Artikel lesen | |
| 06.08. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 22.07. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 29.06. | NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS | 210 | PR Newswire | First randomized, double-blind, placebo-controlled trial to demonstrate treatment-associated reduction of TDP-43 in people living with ALS
TDP-43 pathology is... ► Artikel lesen | |
| 25.06. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| NEUROSENSE THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 25.06. | NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease | 307 | PR Newswire | PrimeC was associated with changes across multiple biomarkers spanning key neurodegenerative disease pathways, providing early biological evidence consistent with... ► Artikel lesen | |
| 18.06. | Halberd Corp.: Halberd Corporation Ships Latest NeuroSense AI Version, Advancing Voice-Based Behavioral Monitoring | 3 | GlobeNewswire (USA) | ||
| 08.06. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 24.04. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 03.04. | NeuroSense Therapeutics receives Nasdaq notices over listing requirements | 20 | Seeking Alpha | ||
| 03.04. | NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements | 306 | PR Newswire | Notifications have no immediate effect on the listing or trading of the Company's securities on Nasdaq
Nasdaq has provided the Company until September 29, 2026... ► Artikel lesen | |
| 31.03. | NeuroSense Therapeutics reports FY results, GAAP EPS of $0.44 | 2 | Seeking Alpha | ||
| 31.03. | NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update | 548 | PR Newswire | 2025 marked transition of PrimeC into a late-stage clinical asset with FDA-cleared Phase 3 program in ALS
Statistically significant survival benefit demonstrated... ► Artikel lesen | |
| 31.03. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 31.03. | NeuroSense Therapeutics Ltd. - 20-F, Annual and transition report of foreign private issuers | 2 | SEC Filings | ||
| 24.03. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 16.03. | NeuroSense: JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity | 419 | PR Newswire | The Journal of the American Medical Association (JAMA Neurology) publication highlights consistent clinical and biomarker findings from NeuroSense PARADIGM Phase... ► Artikel lesen | |
| 11.03. | NeuroSense Therapeutics Ltd. - 6-K, Report of foreign issuer | 6 | SEC Filings | ||
| 10.03. | Roth/MKM initiates NeuroSense stock with buy on ALS drug potential | 5 | Investing.com | ||
| 22.12.25 | NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study | 801 | PR Newswire | Clinical and Biomarker Outcomes Expected to Be Reported in Q1 2026
CAMBRIDGE, Mass., Dec. 22, 2025 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense")... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CARDIOL THERAPEUTICS | 1,880 | -0,53 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
20.07.2026 / 16:41 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,370 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates | Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program Presented Data from... ► Artikel lesen | |
| ONCO-INNOVATIONS | 0,323 | -5,00 % | Onco-Innovations Limited: Onco-Innovations Enters into LOI with Ifowonco for Exclusive Option and Worldwide Licence to LAG-3 Small-Molecule Inhibitor Program | CALGARY, AB / ACCESS Newswire / August 19, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H,WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has entered... ► Artikel lesen | |
| CEL-SCI | 1,300 | -7,14 % | CEL-SCI Corporation: Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients | Peer-reviewed publication highlights Multikine's overall survival benefit in low PD-L1 oral cancer patients and expands scientific awareness as CEL-SCI is preparing to enroll patients in Confirmatory... ► Artikel lesen | |
| MOLECULIN BIOTECH | 0,715 | 0,00 % | Moleculin Biotech, Inc. - 8-K, Current Report | ||
| PDS BIOTECHNOLOGY | 0,194 | +1,84 % | PDS Biotechnology Corp - 8-K, Current Report | ||
| GEOVAX LABS | 0,484 | +0,21 % | EQS-News: GeoVax, Inc.: GeoVax Announces a Warrant Inducement Transaction | EQS-News: GeoVax, Inc.
/ Key word(s): Financial
GeoVax Announces a Warrant Inducement Transaction 26.08.2026 / 14:34 CET/CEST
The issuer is solely responsible for the content... ► Artikel lesen | |
| COCRYSTAL | 0,940 | -3,09 % | Cocrystal Pharma, Inc.: Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors | BOTHELL, Wash., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) ("Cocrystal" or the "Company"), a clinical-stage biotechnology company developing novel therapeutics to meet... ► Artikel lesen | |
| LISATA THERAPEUTICS | 1,390 | +4,51 % | Lisata Therapeutics, Inc.: Lisata Therapeutics Provides Update Following Termination of Merger Agreement | Lisata has filed suit against Kuva Labs Inc. and its subsidiary seeking, among other things, damages for the benefit of its stockholders Lisata's Board of Directors and management continues to evaluate... ► Artikel lesen | |
| DECOY THERAPEUTICS | 2,790 | +0,36 % | Morning Market Movers: Universe Pharmaceuticals, Decoy Therapeutics, Comcast, Larimar Therapeutics See Big Swings | PHILADELPHIA (dpa-AFX) - At 7:40 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| JASPER THERAPEUTICS | 0,710 | +0,20 % | Jasper Therapeutics, Inc.: Jasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders Completed a concurrent... ► Artikel lesen | |
| CHEMOMAB THERAPEUTICS | 2,740 | +1,11 % | Chemomab Therapeutics Ltd.: Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update | Proposed merger with Scipher Medicine to assess nebokitug in a Phase 2 precision medicine trial in rheumatoid arthritis (RA) continues to advance with closing expected by year-end RA is a $24 billion... ► Artikel lesen | |
| VISTAGEN THERAPEUTICS | 0,245 | +0,78 % | Vistagen Therapeutics, Inc.: Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update | Exploratory analyses of patients with very severe social anxiety disorder demonstrated nominally statistically significant improvement in recently reported clinical studies FDA engagement planned... ► Artikel lesen | |
| IN8BIO | 0,970 | +4,86 % | IN8bio, Inc: IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026 | Repeat dosing of DeltExTM Drug Resistant Immunotherapy (DRI) had a median progression-free survival (mPFS) of 13.0 months and median overall survival (mOS) exceeding 19.5 months (not yet reached).... ► Artikel lesen | |
| METAVIA | 1,810 | +3,43 % | MetaVia Inc.: MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update | All Active Patients Successfully Reached Highest Planned Dose Levels of 48 mg and 64 mg in Ongoing Phase 1 Part 3 Study of DA-1726
16-Week Topline Data Expected... ► Artikel lesen |
Das Unternehmen NEUROSENSE THERAPEUTICS LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,014 (-4,38 %) liegt der Kurs bei 0,306 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEUROSENSE THERAPEUTICS LTD finden Sie auf Wallstreet Online.